508-651-3700
Development Services
Benu Biopharma utilizes a “Virtual” business model, with the oversight of a small cadre of highly skilled and experienced biotechnology managers, that enables early stage compounds or biologics to be moved into the clinic and through clinical proof of principle expeditiously and efficiently.
Consulting Services
Benu BioPharma offers biotechnology companies more than 60 years of combined experience in drug and biologic product development, providing advice and experience during the crucial early stages of development. Benu Biopharma provides comprehensive product development, portfolio management and diligence services.
LipimetiX Development
LipimetiX Development’s lead peptide, AEM-28, is an apolipoprotein E mimetic peptide for refractory hypercholesterolemia, coronary artery and peripheral artery diseases, and is currently in preclinical development.
AEM-28 has been extensively validated in the most relevant animal models by a leading academic institution prior to formation of the company. AEM-28 has been granted orphan drug designation from the FDA. >> Visit LipimetiX Development
eXIthera Pharmaceuticals
eXIthera is a clinical stage biotech company focused on discovering and developing effective anticoagulants/antithrombotics without increased bleeding risk or the need for a reversal agent. eXithera presented the results of a Phase 1a/1b clinical study of EP-7041, a novel, small molecule Factor Xia inhibitor, at the 2017 AHA Scientific Sessions. >> See Article
Parenteral administration of EP-7041 resulted in a rapid, predictable increase in aPTT, a standard clinical measure of anticoagulation activity, without affecting PT, indicating no unwanted/unintended effect on the extrinsic pathway.
Benu BioPharma principals served as Senior VP, Research and Development and VPs of Product Development and Clinical Research for eXithera. >> Visit eXIthera Pharmaceuticals
Services
